Because CD16b is expressed on normal myeloid lineages and not on AML, this approach offers the possibility of mitigating myeloid compartment depletion and CRS by specifically blocking healthy-cell-mediated activation of the CD33 | CD16b Tmod cells by normal myeloid cells. The gene discussed is FCGR3B; the disease is acute myeloid leukemia.